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tional trade of food products and live
animals. Large international corpora-
tions may also affect international
trade. For example, McDonald’s
Corporation has issued a global policy
for antimicrobial drug use in food ani-
mals that specifies requirements for
their food product suppliers. Local
groceries or supermarkets may also
impose their own standards national-
ly. We are aware of only 1 product
withdrawal related to antimicrobial
resistance, the quail imported from
France.
No international standards exist
for managing food safety problems
related to antimicrobial resistance.
However, in 2003 the Food and
Agriculture Organization of the
United Nations, WHO, and the World
Organisation for Animal Health joint-
ly hosted a workshop with a panel of
experts to scientifically assess resist-
ance risks related to nonhuman use of
antimicrobial drugs (9). The panel’s
purpose was also to provide recom-
mendations to the Codex
Alimentarius Commission for future
risk management of antimicrobial
drug resistance (9). Imposing restric-
tions on products with combinations
of resistance, such as simultaneous
resistance to quinolones and
cephalosporins in Salmonella, as
reported in this study, would be a
good first step towards managing
antimicrobial drug–resistance risks.
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To the Editor: The use of antimi-
crobial agents for growth promotion
(AGP) in food-producing animals has
been extensively debated because of
the risk of establishing a reservoir of
antimicrobial resistance genes or
antimicrobial-resistant organisms of
potential relevance for human health.
This concern has motivated the pro-
gressive ban of the use of different
AGP in the European Union, which
began in 1997 with avoparcin and will
end in 2006 (1). Worldwide trade of
living animals for food production or
breeding and of meat products
enables multidrug-resistant pathogens
to spread across national borders. 
Intercontinental dissemination of
antimicrobial-resistant bacteria asso-
ciated with food animals has been
described for particular clones such as
Salmonella enterica Typhimurium
DT104 or Escherichia coli O157:H7
and for transferable genetic elements
such as the genomic island SG1 or the
streptococcal plasmid pRE25 (2).
Vancomycin-resistant enterococci
(VRE) in European farms were ini-
tially associated with the intensive use
of avoparcin; however, the persist-
ence of VRE in food animal environ-
ments after years of avoparcin with-
drawal indicates that coselection by
further antimicrobial or other agents,
increased fitness of strains, and
mobile genetic elements cannot be
ruled out (1–3).
A specific clone was recently
detected among vancomycin-resistant
E. faecium (VREF) isolated from dif-
ferent swine farms in Denmark and
Switzerland and from a healthy
Danish woman without antimicrobial
drug exposure who ate pork, chicken,
and beef (4,5). Since Portugal and
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Spain maintain commercial trade of
food-producing swine (living or meat
products) between them and with
other European countries, including
Denmark (http//:www.dgv.min-agri-
cultura.pt/dgv.nsf), we investigated a
possible relationship among VREF
swine fecal isolates from Portugal and
Spain and compared these isolates
with the Swiss/Danish clone. We stud-
ied 3 VREF from a Figueira da Foz
slaughterhouse in central Portugal
(1997–1998) and 3 VREF isolates
from 3 Spanish slaughterhouses in
Valencia, Lugo, and Murcia in east-
ern, northern, and southern Spain,
respectively (1998–2000). These iso-
lates were recovered in the course of
previous surveillance studies (C.
Novais/I. Herrero, unpub data).
Antimicrobial susceptibility was test-
ed for 13 antimicrobial agents by
using the agar dilution method (6).
Clonal relationships were analyzed by
pulsed-field gel electrophoresis
(PFGE) and characterization of pur-K
alleles by amplification and further
sequencing (6,7; http://efaecium.
mlst.net). Species identification,
genes coding for antimicrobial resist-
ance genes or for putative virulence
traits, and the backbone structure of
Tn1546 were analyzed by polymerase
chain reaction followed by sequenc-
ing when necessary (6,8). Broth and
filter mating were performed by using
E. faecium GE1 as recipient strain (6). 
Following criteria published else-
where (6), the VREF isolates studied
were considered a single clone (0–4
bands difference by PFGE). Some
vancomycin-susceptible  E. faecium
swine isolates (VSEF) from Spain and
Switzerland showed an SmaI-PFGE
pattern closely related to that of
VREF isolates (data not shown; [4]).
Representative VREF of each
country harbored the allele 9 of the
housekeeping gene purK, previously
found among E. faecium isolates from
swine and healthy persons (7). All
VREF isolates were resistant to gly-
copeptides (vanA), erythromycin
[erm(B)], and tetracycline. Two
Spanish isolates were also highly
resistant to streptomycin and
kanamycin [aph(3′)-IIIa] (Table). All
VREF isolates tested carried a
Tn1546 type D, previously found in
isolates from food-producing animals
(8). This element showed alterations
in orf1 and a G-T point mutation in
the position 8234 at vanX. Transfer of
vancomycin resistance was detected
for the Swiss (4), Spanish, and
Portuguese isolates and was associat-
ed with erythromycin resistance in all
cases. Tetracycline resistance was
also transferable in the Spanish
strains. No virulence traits were
detected. 
We describe the simultaneous
occurrence of a VREF strain among
swine in 4 distant European countries
for at least a 4-year period. Tn1546
type D has been largely described in
European swine isolates, which indi-
cates stability of this particular type
among the high diversity of Tn1546
described to date (8). The finding of a
group of genetically closely related
strains, which include both VSEF and
VREF isolates and which harbor a
particular  purK allele previously
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associated with E. faecium swine
strains, might mirror wide dissemina-
tion of a host-specific clone more
prone than others to acquire and
spread different antimicrobial resist-
ance, as reported for human clinical E.
faecium isolates (9). Since enterococ-
ci from swine are able to colonize in
the human gut (5,7) and isolates har-
boring purK-9 can be recovered from
hospitalized patients with severe
infections (10), specific swine entero-
coccal strains might represent a risk
for antimicrobial resistance spread in
the clinical setting. Further analyses
need to be performed to understand
the role of international animal move-
ments, animal feed, and colonized
farmers in the spread of this particular
strain and to assess whether this clone
shows an increased fitness in the
porcine intestine when compared to
other E. faecium strains.
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Rabies Vaccine
Baits, Pennsylvania
To the Editor: Oral rabies vaccine
(ORV) programs control rabies in ter-
restrial reservoir species by distribut-
ing vaccine in baits (1). The current
US-licensed ORV consists of a rabies
virus glycoprotein gene inserted into
the thymidine kinase gene of an atten-
uated strain of the Copenhagen vac-
cinia virus (V-RG) (2). Safety experi-
ence includes extensive animal stud-
ies (2,3) in which significant adverse
effects were seen only with parenteral
(but not mucosal) exposure of nude
mice to V-RG (4). Usage monitoring
(4,5) found only 1 human adverse
complication to date (6). 
We report our experience monitor-
ing pet and human exposure to V-RG
as part of a multiagency federal-state
cooperative program that distributed
1,710,399 V-RG-laden baits from
August 11, 2003, to September 17,
2003, over 25,189 km2 of western
Pennsylvania (human population ≈3
million). The baits consisted of a vac-
cine-filled plastic sachet surrounded
by a fishmeal polymer. Workers dis-
tributed these baits on the ground from
vehicles or by air from fixed-wing air-
craft using conveyor belts. Aircraft did
not release baits when over homes or
other areas where humans or pets were
likely to be present. Given the limita-
tions of dispersing 1,421,517 baits at a
frequency of 75 to 150 baits/km2 from
200 m in the air, human habitat could
not be totally avoided.
Each bait was printed with a toll-
free phone number. Phone calls were
routed to a local or district health
department where an ORV-specific
form adapted from the Ohio State
Health Department was used to col-
lect uniform information about bait
contact.
During the 2003 campaign,
Pennsylvania health departments and
districts received 105 reports from
persons who found 190 baits. This
rate of reporting, 6.1 per 100,000
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 12, December 2005 1987